Document Detail


Challenges in the use of NG2 antigen as a marker to predict MLL rearrangements in multi-center studies.
MedLine Citation:
PMID:  21444110     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Rearrangements in MLL (MLL-r) are common within very young children with leukemia and affect the prognosis and treatment. Previous studies have suggested the use of the NG2 molecule as a marker for MLL-r but these studies were performed using a small number of infants. We analyzed 148 patients (all less than 24 months, 86 less than 12 months) from various centers in Brazil to determine the predictive power of NG2 within that cohort. We show that NG2 can be used for MLL-r prediction; however, proper staff training and standardized sampling procedures are essential when receiving samples from multiple centers as the accuracy of the prediction varies greatly on a per center basis.
Authors:
Mariana Emerenciano; Gabriel Renaud; Mariana Sant'ana; Caroline Barbieri; Fabio Passetti; Maria S Pombo-de-Oliveira;
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-26
Journal Detail:
Title:  Leukemia research     Volume:  -     ISSN:  1873-5835     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier Ltd.
Affiliation:
Pediatric Hematology and Oncology Program, Research Center, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association of non-reassuring fetal heart rate and fetal acidosis with placental histopathology.
Next Document:  Pain and quality of life with chronic obstructive pulmonary disease.